[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Zurich\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":647},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,101,0,25,[9,42,70,97,119,141,178,199,225,255,281,305,325,352,377,412,430,448,479,504,527,556,584,602,623],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100639087","weekly-online-ct-or-mr-adaptive-definitive-sbrt-for-very-high-risk-localized-or-regionally-metastatic-prostate-cancer-100639087",false,"NCT07591051","Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer","Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer (WARP)","WARP","Inclusion criteria include:\n\n* Regionally metastatic prostate cancer (cN1, any T, Gleason 6-10, any PSA) according to NCCN guidelines consisting of ≤ 5 regional lymph node metastases\n* Good to moderate performance status (WHO 0-2)\n* Written informed consent.\n* A PSMA PET and multiparametric MRI is mandatory according to staging guidelines.\n* Age ≥ 18 years\n\nExclusion criteria include:\n\n* \\>5 regional lymph nodes\n* Patients with cT4 disease (tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and\u002For pelvic wall)\n* Previous radiotherapy to the pelvis or prostate\n* Previous radical prostatectomy\n* Large body size that would not fit into the MRI-simulator bore\n* Presence of distant metastases (i.e. cM1)\n\n  * Non-regional lymph nodes (M1a):\n  * Bone metastases (M1b)\n  * Other sites (M1c)\n* Contraindications to CT or MR-adaptive SBRT (e.g., pacemakers, severe claustrophobia).\n* Severe comorbidities that may interfere with treatment or follow-up (e.g. inflammatory bowel disease).\n* Significant concomitant diseases (e.g. hepatic dysfunction, cardiovascular disease, etc.).\n* Inability to follow procedures or insufficient knowledge of project language, inability to give consent.\n* Participation in a clinical trial which might influence the results of this project.\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.\n* Severe genitourinary or gastrointestinal symptoms (e.g. recent urinary retention or diarrhea ≥ grade 3 or obstipation to CTCAE v.6.0).\n* Severe urinary symptoms (e.g. IPSS \\>12 and\u002For prostate volume \\> 80 mL)","MALE","18 Years",{"count":21,"type":22},54,"ESTIMATED","INTERVENTIONAL",[25],"NA","This interventional prospective multicenter international study will include 54 patients with regionally metastatic (i.e. cN1 cM0) prostate cancer according to the NCCN criteria.\n\nPatients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.\n\nThis study is classified as risk category A according to ClinO, Art. 61, as stereotactic radiotherapy (SBRT) for regionally metastatic prostate cancer has been extensively evaluated in prospective interventional trials and is considered an established therapeutic modality.\n\nWeekly CT- or MR-guided online adaptive SBRT to the prostate and elective pelvic lymph nodes with 5 × 5 Gy is, however, not yet routinely implemented for this specific patient population.\n\nA diagnostic high field MRI during radiotherapy, e.g. week 3 is optional.\n\nFollow-up is also according to standard of care (except for patient reported outcome measure using QLQ-C30 and QLQ-PR25 and a diagnostic MRI at 9 months after SBRT (optional), and 12 months in the case of an image non-complete response at 9 months (optional).",[28],"Prostate Cancer","NOT_YET_RECRUITING","2026-08-19",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":22},"2027-01",{"date":37,"type":22},"2033-01",{"name":39,"class":40},"University of Zurich","OTHER",2,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100583013","comparing-closed-face-masks-vs-surface-guided-radiation-therapy-for-head-and-neck-radiotherapy-100583013","NCT06870799","Comparing Closed Face Masks vs Surface Guided Radiation Therapy for Head and Neck Radiotherapy","Randomized Controlled Trial Comparing Closed Face Masks vs Surface Guided Radiation Therapy for Head and Neck Radiotherapy","NoMask","Inclusion Criteria:\n\n* Written informed consent according to Swiss law and ICH\u002FGCP regulations before any trial specific procedures;\n* Indication for head and neck radiotherapy irrespective of tumor type;\n* Age: ≥ 18 years old;\n* Karnofsky performance status ≥70;\n* Patients who are willing and able to comply with scheduled visits, treatment, and other trial procedures.\n\nExclusion Criteria:\n\n* Prior head and neck irradiation;\n* Women who are pregnant or breast feeding;\n* Intention to become pregnant during the course of the trial;\n* Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases;\n* Known or suspected non-compliance, drug or alcohol abuse;\n* Inability to follow the procedures of the trial, e.g. due to language problems of the participant;\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.\n* One of the following Tumor Types: Nasopharynx, Sinunasal, patients with CTV within 5 mm of eyes or spinal cord.","ALL",{"count":7,"type":22},[25],"At present, open-face masks are used only in patients with claustrophobic anxiety, while all other patients are still immobilized with closed masks, thereby overlooking the need for improvement in patient comfort. Closed face masks in patients undergoing head and neck irradiation have never been compared to no masks in the setting of a randomized clinical trial, but only in feasibility trials. A randomized clinical trial may establish the role of no masks in terms of patient comfort, preference and setup accuracy in all patients.",[55],"Head and Neck Cancers",[57,58,59,60],"head and neck cancer","face mask","surface guidance","radiation therapy","RECRUITING",{"date":63,"type":33},"2026-08-20",{"date":65,"type":33},"2025-05-12",{"date":67,"type":22},"2027-05",{"name":39,"class":40},1,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100559379","phase-2-personalized-volume-deescalated-elective-nodal-irradiation-in-oropharyngeal-head-and-neck-squamous-cell-carcinoma-100559379","NCT06563362","Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma","Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck","DeEscO","Inclusion Criteria:\n\n* Patients with a newly diagnosed (no pre-treatment) squamous cell carcinoma of the oropharynx (i.e. tonsils, base of tongue, oropharyngeal walls, oropharyngeal surface of epiglottis; ICD-10 codes C01, C09, C10), T1-4, N0-3.\n* Treatment with definitive (chemo) radiotherapy planned, with elective irradiation of the lymph nodes.\n* Age ≥ 18 years, no upper age limit.\n* ECOG performance score \\\u003C 3.\n* History\u002Fphysical examination within 30 days prior to study inclusion by head and neck surgeon and\u002For radiation oncologist.\n* FDG-PET scan prior to study inclusion. In case of inability to perform or contra-indication, at least contrast enhanced MRI scan obligatory.\n* Participants need to provide informed consent.\n\nExclusion Criteria:\n\nInclusion Criteria:\n\n* Patients with a newly diagnosed (no pre-treatment) squamous cell carcinoma of the oropharynx (i.e. tonsils, base of tongue, oropharyngeal walls, oropharyngeal surface of epiglottis; ICD-10 codes C01, C09, C10), T1-4, N0-3.\n* Treatment with definitive (chemo) radiotherapy planned, with elective irradiation of the lymph nodes.\n* Age ≥ 18 years, no upper age limit.\n* ECOG performance score \\\u003C 3.\n* History\u002Fphysical examination within 30 days prior to study inclusion by head and neck surgeon and\u002For radiation oncologist.\n* FDG-PET scan prior to study inclusion. In case of inability to perform or contra-indication, at least contrast enhanced MRI scan obligatory.\n* Participants need to provide informed consent.\n\nExclusion Criteria:\n\n* Multilevel primary tumors extending unambiguously beyond the oropharynx into the oral cavity, naso- or hypopharynx\n* Distant metastases detected.\n* Previous surgery, chemotherapy or radiotherapy treatment for other head and neck cancers.\n* Previous surgery in head and neck region affecting the cervical lymphatic system. Dissection of singular lymph nodes for diagnostic purposes before treatment start is allowed.\n* Synchronous or previous malignancies. Exceptions are curatively treated basal cell carcinoma or SCC of the skin, or in situ carcinoma of the cervix uteri, low- or intermediate- risk prostate cancer or breast with a progression-free follow-up time of at least 3 years without any remaining disease burden, or other previous malignancy with a progression-free interval of at least 5 years without any remaining active\u002Fprogressive disease burden regardless whether the treatment is completed or ongoing as a maintenance treatment (e.g. androgen deprivation therapy for prostate cancer).\n* Pregnancy or breast feeding\n* Any severe mental or psychic disorder affecting decision making and ability to provide informed consent.",{"count":79,"type":22},120,[81],"PHASE2","Multicentric prospective model-based de-escalation of the elective clinical target volumes (CTV) in radiotherapy of oropharyngeal carcinoma of all stages with the goal to reduce toxicity.\n\nThe study investigates the feasibility of this approach as measured by the number of expected out-of-field recurrencies based on the individual patient's state of disease progression and risk factors",[84],"Oropharynx Cancer",[57,86,87,88,89],"radiotherapy","elective CTV","clinical target volume","de-escalation",{"date":32,"type":33},{"date":92,"type":33},"2025-02-04",{"date":94,"type":22},"2030-02-28",{"name":39,"class":40},7,{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100484923","phase-1-dose-escalation-for-sbrt-of-recurrent-vt-ventricular-tachyarrhythmia---a-single-center-phase-ii-clinical-trial-100484923","NCT05594368","Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial","Dose Escalation for Stereotactic Cardiac Radiation Therapy of Recurrent Ventricular Tachyarrhythmia - a Multi Center, Phase II Clinical Trial","DEFT STAR","Inclusion Criteria:\n\nPatients with structural heart disease, in particular ischemic and non-ischemic cardiomyopathy: Implanted ICD and\u002For CRT-D. Prior ≥1 failed catheter ablation (with endocardial ± epicardial approach based on the substrate location and the ECG morphology of clinical VTs) procedure to control sustained monomorphic VT using currently recommended mapping and ablation techniques,2 or patients in whom ablation is not feasible. Reasons for lack of epicardial ablation and non-feasibility of catheter ablation must be specified. Sustained VT recurrence after catheter ablation on optimised antiarrhythmic medication.\n\nAge ≥18 years. IRB-approved, written informed consent must be provided\n\nExclusion Criteria:\n\nPatients with only premature ventricular contractions.\n\nPatients with sustained VT\u002FVF who demonstrate:\n\nAcute myocardial infarction; Primary electrical disease (channelopathy); Reversible and treatable cause (e.g., drug-induced or intoxication) of VT that can be adequately addressed otherwise; A target that cannot be safely and precisely defined based on stereotactic radiotherapy accuracy requirements (e.g., anatomical interference from OARs, overlapping prior radiation therapy to the thoracic region); Pregnancy or breastfeeding; Inability to provide informed consent.",{"count":106,"type":22},15,[108],"PHASE1","The objective of this study is to demonstrate that higher radiation doses are necessary to induce transmural scar formation which is currently assumed to be the underlying mechanism of successful long-term efficacy of VT treatment and therefore dose-escalation will lead to a significantly reduced long-term VT recurrence rate compared to the currently applied single dose of 25 Gy.",[111],"Ventricular Tachycardia",{"date":32,"type":33},{"date":114,"type":33},"2022-07-01",{"date":116,"type":22},"2028-12-31",{"name":39,"class":40},3,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":69},"100612307","supercable-vs-conventional-steel-wire-for-closure-after-a-median-sternotomy-100612307","NCT07251881","SuperCable vs. Conventional Steel Wire for Closure After a Median Sternotomy","Prospective-randomized Trial to Demonstrate Superiority of SuperCable vs. Conventional Steel Wire for Closure After a Median Sternotomy","SURE","Inclusion Criteria:\n\n* Provision of Informed Consent: The subject must have signed and dated the informed consent form prior to any study-related procedures.\n* Willingness and Ability to Comply: The subject must express a stated willingness to comply with all study procedures and be available for the duration of the study.\n* Age and Sex:\n\n  * Age: The subject must be at least 18 years old.\n  * Sex: Both male and female subjects are eligible. In line with the \"Sex and Gender in Research Involving Humans\" recommendations, data will be stratified and analyzed by sex to identify any potential differences in outcomes.\n* Language Competence: The subject must possess sufficient German language skills to accurately complete the postoperative survey\n* Travel Capability: The subject must have the ability to travel for all planned study visits, including scheduled CT scans\n* Surgical Procedure: The subject must be scheduled for elective coronary artery bypass graft (CABG) procedures, as this is the focus of the investigation\n* Adherence to Visit Schedule: The subject must be willing to adhere to all scheduled visits and undergo CT scans as outlined in the study protocol\n\nExclusion Criteria:\n\n* Pharmacological Restrictions: Current use of corticosteroids or any immunosuppressive medication\n* Prior Treatments and Therapies: History of radiation therapy to the thorax\n* Reproductive Considerations:\n\n  * Pregnancy, or the intent to become pregnant during the study period\n  * Lactation or current breastfeeding\n* Allergic Reactions: Known allergic reactions to components of the conventional steel wire or SuperCable, specifically any known metal allergies (e.g., nickel or titanium).\n\nExample: Patients with a documented history of nickel allergy, including previous adverse reactions to products such as sternal cerclages, will be excluded\n\n* Infectious or Febrile Conditions: Any febrile illness occurring immediately before the scheduled surgery\n* Concurrent Investigational Treatments: Treatment with another investigational drug or medical device within two months preceding surgery, as well as during the current investigation\n* Surgical History: Subjects who have undergone prior sternotomy and osteosynthesis (i.e., re-do patients) will be excluded\n* Anatomical Considerations:\n\n  * Known sternal deformities that could compromise the outcome of the investigation\n  * Off-midline sternotomy approaches, as these do not align with the surgical technique under investigation\n* Patient Residence and Follow-Up Feasibility: Subjects residing in remote regions, including those from interstate or overseas, where follow-up and adherence to the scheduled visits might be compromised\n* Other Specific Exclusions: Any additional criteria specific to the disease under investigation or identified by the investigator based on medical judgment (e.g., clinically significant concomitant disease states such as renal failure, hepatic dysfunction, or cardiovascular disease, if these conditions are deemed to interfere with study outcomes)",{"count":128,"type":22},86,[25],"During certain heart surgeries, the sternum is opened and must then be closed securely. The study compares two closure methods - steel wires and SuperCable - in terms of stability, healing, and patient satisfaction. This investigation aims to demonstrate that the iso-elastic properties of the SuperCable Sternal Closure System result in faster sternal bone healing, reduced postoperative pain, shorter hospital stay, and improved physical recovery compared to conventional steel wire sternal closure. Eighty-six patients are participating and are randomly assigned to one of the two groups. After the operation, pain, healing, and possible complications are checked. The patients are examined 3 and 6 months after the operation.",[132],"Sternotomy","2026-07-29",{"date":135,"type":33},"2026-07-30",{"date":137,"type":33},"2026-05-29",{"date":139,"type":22},"2027-07",{"name":39,"class":40},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":150,"minAge":19,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":155,"conditions":156,"keywords":160,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":69},"100646741","assessment-of-metabolic-changes-in-response-to-glcuose-intake-in-women-with-polyendocrine-metabolic-ovarian-syndrome-pmos-100646741","NCT07687264","Assessment of Metabolic Changes in Response to Glcuose Intake in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS)","METabolic FLEXibility in PMOS","METFLEX","Inclusion Criteria:\n\n* Age: 18-35 years\n* Body weight (BMI): between BMI 18.5-39.9 kg\u002Fm2\n* Ability to consent and to provide written informed consent\n* CG: History of regular MCs (21 to 35 days) 3 months prior to study enrollment\n* PCOS-G: Existing or new established diagnosis of PCOS. Diagnosis is verified in accordance with the ESHRE\u002FASRM Rotterdam consensus (2003)23, phenotype A (hyperandrogenism, oligo-\u002Fanovulation, and polycystic ovarian morphology). PCOS is diagnosed when at least the following three criteria are present, after exclusion of other etiologies:\n\n  * Oligo- or anovulation\n  * Clinical and\u002For biochemical signs of hyperandrogenism\n  * Polycystic ovaries on ultrasound (≥12 follicles per ovary measuring 2-9 mm in diameter and\u002For ovarian volume \\>10 mL)\n\nExclusion Criteria:\n\n* Use of systemic hormonal contraceptives within the last 3 months prior to study enrollment. Use of levonorgestrel-releasing intrauterine devices is permitted; all other hormonal contraceptive methods are excluded.\n* CG: A clinically diagnosed or history of a menstrual disorder (e.g., polycystic ovarian syndrome (PCOS), premenstrual dysphoric disorder (PMDD) or amenorrhea)\n* A clinically diagnosed mental disorder (e.g. major depression, anxiety disorder)\n* history of epileptic seizure\n* history of or current manic or psychotic episode\n* existing\u002Fcurrent eating disorders (bulimia nervosa, anorexia nervosa) within the past 5 years\n* inability to communicate adequately in speech\n* inability to follow instructions\n* regular use of medication other than thyroxine\n* alcohol consumption as equivalent doses of more than 12 g of pure alcohol per day\n* vegan diet\n* daily nicotine consumption\n* currently or history of (regular) consumption of illegal drugs within the last year\n* pregnancy or breastfeeding\n* known diseases of the cardiovascular system\n* arterial hypertension above 160\u002F90 mm\u002FHg at rest\n* known pulmonary diseases\n* Arthritis and rheumatic diseases and conditions\n* Hematologic diseases\n* surgery less than 1 month ago\n* having given birth within 12 months before the start of the study",true,"FEMALE","35 Years",{"count":153,"type":22},40,[25],"Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome (PCOS), is a common endocrine and metabolic condition affecting women of reproductive age. It is associated with hormonal imbalances, irregular menstrual cycles, elevated androgen levels, and metabolic disturbances such as insulin resistance. These metabolic changes can increase the risk of type 2 diabetes and cardiovascular disease.\n\nInsulin resistance means that the body's cells respond less effectively to insulin, a hormone that regulates blood glucose. This leads to compensatory increases in insulin levels, which can further disrupt hormonal balance and contribute to the clinical features of PMOS.\n\nThis study aims to investigate how the bodies of women with PMOS respond dynamically to glucose intake compared with women without PMOS. A standard clinical test, the oral glucose tolerance test (oGTT), will be used. Participants consume a glucose solution, and blood samples are collected before and two hours afterward. This procedure is routinely used in clinical practice.\n\nWomen with PMOS will be compared with age- and body mass index (BMI)-matched control participants without PMOS. Blood and urine samples will be analyzed using advanced multi-omics technologies to measure proteins, metabolites, extracellular vesicles, and immune-related signals.\n\nThe main objective is to understand how metabolic, hormonal, and immune pathways respond over time to a glucose challenge and whether these responses differ in PMOS. Special attention is given to inter-organ communication and systemic metabolic regulation.\n\nThe study includes two visits. The first visit involves health assessments, questionnaires, and body composition measurements. The second visit includes the glucose tolerance test and blood sampling. In total, approximately 100 mL of blood will be collected across both visits.\n\nParticipation is voluntary, and participants may withdraw at any time without affecting their medical care. The procedures involve minimal risk and consist of standard clinical methods.\n\nThe results of this study may improve understanding of PMOS and contribute to better diagnostic and therapeutic strategies in the future.",[157,158,159],"PCOS (Polycystic Ovary Syndrome)","Insulinemic Response","Overweight (BMI > 25)",[161,162,163,164,165,166,167,168,169],"PMOS","PCOS","oGTT","multi-omics","plasma proteomics","metabolomics","steroid hormones","inflammation","cytokines","2026-07-03",{"date":172,"type":33},"2026-07-07",{"date":174,"type":22},"2026-08-01",{"date":176,"type":22},"2029-07-30",{"name":39,"class":40},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":149,"sex":50,"minAge":19,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":69},"100451830","the-acute-cardiorespiratory-response-to-blood-flow-restricted-versus-traditional-exercise-training-regimens-care-bfr-100451830","NCT05163600","The Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR)","The Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR):4 Randomized Crossover Studies","CaRe-BFR","Inclusion and exclusion for the healthy participants are defined by the following criteria.\n\nInclusion criteria:\n\n* Age ≥ 18 years\n* Clinically healthy\n\nExclusion criteria:\n\n* Physical or intellectual impairment precluding informed consent or protocol adherence\n* Non-German speaking (precluding informed consent)\n* Pain during exercise of any origin\n* Pregnancy\n* History of thromboembolic event in the lower extremity\n* Resting systolic blood pressure \\\u003C100 mmHg\n\nInclusion and exclusion for the COPD participants are defined by the following criteria.\n\nInclusion criteria:\n\n* Age ≥ 18 years\n* Diagnosed COPD according to GOLD-guidelines12\n\nExclusion criteria:\n\n* Physical or intellectual impairment precluding informed consent or protocol adherence\n* Non-German speaking (precluding informed consent)\n* Acute or recent (within the last 6 weeks) exacerbation of COPD\n* Pain during exercise of any origin\n* Pregnancy\n* History of thromboembolic event in the lower extremity\n* Resting systolic blood pressure \\\u003C100 mmHg","90 Years",{"count":188,"type":22},24,[25],"The investigators hypothesize that BFR exercise regimens result in a different acute cardiorespiratory response pattern compared to traditional exercise regimens. Furthermore, the investigators hypothesize that these patterns differ between healthy participants and participants with COPD.\n\nRegarding secondary objective, the investigators hypothesize that BFR results in lower blood pressure responses compared to traditional exercise training in both healthy and COPD participants.",[192],"COPD",{"date":172,"type":33},{"date":195,"type":33},"2022-05-20",{"date":197,"type":22},"2026-12-31",{"name":39,"class":40},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":69},"100596192","feasibility-of-mr-informed-adaptive-marker-less-sbrt-in-patients-with-bilateral-hip-prostheses-undergoing-sbrt-for-localized-prostate-cancer-100596192","NCT07042256","Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer","HIP-PRO","Inclusion Criteria:\n\n* Diagnosis of localized prostate cancer suitable for definitive SBRT based on a multidisciplinary tumour board recommendation and \u002F or clinical practice guideline.\n* Presence of bilateral hip prostheses labeled as MR safe or MR-conditional.\n* ECOG performance status ≤ 2.\n* Signed informed consent.\n* Age ≥18 years -\n\nExclusion Criteria:\n\n* Large body size that would not fit into the MRI-simulator bore\n* Hip prosthesis that are labeled as MR unsafe;\n* Contraindications to MRI including but not limited to:\n\n  * Claustrophobia unmanageable by sedation\n  * Electronic devices such as pacemakers, defibrillators, deep brain stimulators, cochlear implants that are labeled as MR unsafe, electronic devices labeled as MR safe or MR conditional are not a contraindication;\n  * Metallic foreign body in the eye or aneurysm clips in the brain;\n* Clinically significant concomitant diseases that would interfere with the study (e.g. hepatic dysfunction, cardiovascular disease).\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.",{"count":207,"type":22},13,[25],"Hip replacements and prostate cancer are independently and both together increasing prevalent in the aging population. In the United States, the prevalence of hip prostheses among men was 1.1 million in 20101, with approximately 500,000 hip prostheses performed annually. Bilateral total hip replacement is recommended for patients with osteoarthritis affecting both hip joints. Approximately 10-25% of total hip replacement patients undergo bilateral procedures. Stereotactic body radiotherapy (SBRT) has been widely adopted as an effective treatment for localized prostate cancer, offering high precision and reduced treatment time due to conventionally fractionated radiotherapy without increasing toxicity or comprising oncological outcomes. Therefore, the use of SBRT for treatment of localized prostate cancer has significantly increased. A cohort study using data from 302 035 patients in the National Cancer Database showed that use of SBRT for prostate cancer increased from 0.2% in 2004 to 12.4% in 2020 in the United States.\n\nHowever, both CT and MR-guided SBRT present unique challenges for patients with prostate cancer and bilateral hip prostheses. Metallic implants, such as hip prostheses, produce artifacts and magnetic susceptibility issues that can obscure MR imaging near the prosthetic sites, potentially complicating target contouring and planning. Given the close proximity of the prostate gland to the pelvis, which houses the hip joints, patients with bilateral hip prostheses may have significant imaging artifacts that could impair MR-guided radiotherapy quality. CT-based SBRT is less affected by metallic artifacts, but it lacks the soft-tissue resolution needed for precise prostate and OAR delineation, a gap MR imaging is uniquely positioned to fill.\n\nLow-field MRI systems are less prone to susceptibility artifacts, including those originating from metallic implants. As a result, signal loss and distortion are expected to occur only in the immediate vicinity of the implant, making these systems particularly advantageous for imaging patients with hip implants. A prospective study quantitatively and qualitatively compared the magnitude of metal total hip arthroplasty-induced imaging artifacts in vivo between 1.5T (i.e. high-field) and 0.55T (low-field) MRI in 15 patients. Qualitative artifact magnitude was on average rated as moderate to small on 0.55T and as large to moderate on 1.5T by 2 fellowship-trained musculoskeletal radiologists. In addition, metal artifacts' areas and diameters were smaller on 0.55T when compared with 1.5T MRI for all sequences (each p\\>0.016).\n\nGiven the limitations of current imaging systems, the investigators propose a more flexible solution: a two-room system comprising a low-field MRI scanner for optimal image quality and a C-arm linear accelerator for rapid treatment delivery. Patient transfer between the MR device and the linear accelerator will be performed with a shuttle system which uses an air-bearing patient platform for both procedures. This setup would allow for high-quality imaging with reduced artifacts while ensuring efficient treatment times, addressing the current gap in SBRT for patients with bilateral hip prostheses. This shuttle system is MR-compatible and uses an air-bearing technology that allows the patient to be effortlessly moved by a transfer sled from MR scanner couch to linac without any movement on their part as it utilises the same patient platform with treatment using supports, immobilization devices and stereotactic tools for both procedures. This means that the patient is scanned and treated in the same position, minimising the risk of translational and\u002For rotational positional changes during transfer between both devices. Thus, maximum use of image-based planning data is possible. By integrating a low-field MRI scanner with a dedicated treatment delivery system, the investigators can overcome existing limitations and improve treatment precision for this growing patient population.",[211],"Localized Prostate Adenocarcinoma",[213,214,215,216],"Bilateral hip prostheses","SBRT","Stereotactic body radiotherapy","prostate cancer","2026-07-01",{"date":219,"type":33},"2026-07-06",{"date":221,"type":33},"2026-06-09",{"date":223,"type":22},"2031-09-30",{"name":39,"class":40},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":236,"conditions":237,"keywords":242,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":118},"100580196","online-adaptive-stereotactic-body-radiotherapy-for-localized-prostate-cancer-100580196","NCT06834152","Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer","Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer in Patients With Lower Urinary Tract Symptoms and\u002For Prostate Hyperplasia (X-SMILE)","X-SMILE","Inclusion Criteria:\n\n* histologically confirmed localized prostate cancer\n* planned treatment is SBRT according to standard of care and consists of definitive CT or MRI online adaptive SBRT of the prostate according to the PACE trial which includes a total dose to clinical target volume 1 (CTV1, i.e. prostate and proximal 1 cm of the seminal vesicle) of 40.0 Gy in 5 weekly fractions (single dose of 8.0 Gy) and total dose to planning target volume 1 (PTV1) of 37.5 Gy in 5 weekly fractions (single dose of 7.5 Gy) with a compromise for bowel sparing allowed. For patients with unfavorable intermediate to very high-risk disease (according to NCCN guidelines) a total dose to the planning target volume 2 (PTV2, i.e. proximal 1-2 cm of the seminal vesicle) of 32.5 Gy in 5 weekly fractions (single dose of 6.5 Gy) will be delivered.\n* intermediate to (very) high risk localized prostate cancer (≤ cT3a and Gleason score ≤ 9 and\u002For PSA ≤ 20 ng\u002Fml)\n* prostate volume \\> 60 cc and\u002For IPSS \\> 12;\n\nExclusion Criteria:\n\n* Very high risk localized prostate cancer with indication for ADT and ARPI (i.e. Gleason ≥ 8 and cT3a)\n* Involvement of seminal vesicles (cT3b)\n* Contraindications against definitive CT or MRI-adaptive radiotherapy of the prostate, e.g. inflammatory bowel disease (IBD); previous radiotherapy in the pelvis, previous local radiotherapy of the prostate, contraindication for MRI or CT;\n* Patients with severe genitourinary symptoms (e.g. recent urinary retention ≥ grade 3 according CTCAE v.5.0);\n* Lymph node metastases or distant metastases (i.e. no localised prostate cancer);\n* Participation in a clinical trial which might influence the results of this project.",{"count":234,"type":22},75,"OBSERVATIONAL","The aim of this phase II international multicenter study is to evaluate the safety, feasibility, and efficacy of CT or MRI-adaptive SBRT, delivered in five weekly fractions, in patients with newly diagnosed localized prostate cancer who have lower urinary tract symptoms and\u002For prostatic hyperplasia.",[238,239,240,241],"Localized Prostate Carcinoma","Prostate Cancer (Adenocarcinoma)","Prostate Hyperplasia","Lower Urinary Track Symptoms",[86,214,243,244,245,246,247,248,216],"MRI","CT","stereotactic radiotherapy","localized prostate cancer","lower urinary tract symptoms","prostate hyperplasia",{"date":219,"type":33},{"date":251,"type":33},"2024-03-01",{"date":253,"type":22},"2031-06-30",{"name":39,"class":40},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":23,"phases":265,"briefSummary":266,"conditions":267,"keywords":270,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":69},"100646735","daily-adjustment-of-the-radiation-dose-in-mri-guided-stereotactic-radiotherapy-for-tumors-in-the-abdominal-and-pelvic-regions-100646735","NCT07687147","Daily Adjustment of the Radiation Dose in MRI-guided Stereotactic Radiotherapy for Tumors in the Abdominal and Pelvic Regions","Adaptive Fractionation in Online MR-guided SBRT for Abdominal and Pelvic Target Volumes","ACTION","Inclusion Criteria:\n\n* Karnofsky performance status ≥70\n* Abdominal or pelvic malignancy (primary or secondary) with previous histological confirmation of the primary tumour, amenable to SBRT in 5 fractions (excluding SBRT to primary tumour in patients with prostate cancer) Note: patients with primary prostate cancer are eligible, but SBRT to the primary tumour in the prostate cannot be performed within the study\n* Total prescribed SBRT dose \\> 30 Gy (constraint for dose-limiting OAR) over 5 treatment fractions\n* Distance of the GTV ≤ 1 cm from at least one dose-limiting OAR (bowel \u002F duodenum \u002F stomach) in the available diagnostic images\n* Patients able to tolerate long (approximately 60 minutes) treatment time according to clinical evaluation of the treating radiation oncologist\n* Patients willing and able to comply with scheduled visits, treatment, and other trial procedures\n\nExclusion Criteria:\n\n* Previous radiation therapy directly overlapping with planned SBRT (type I re-irradiation)\n* More than one PTV irradiated in the same plan\n* Contraindications for MRI, e.g., patients with metal fragments or implanted devices that are not MR compatible such as certain types of pacemakers and aneurysm clips or severe claustrophobia\n* SBRT not indicated or not possible\n* Inability to follow the procedures of the trial, e.g. due to language problems of the participant",{"count":264,"type":22},100,[25],"SBRT delivers high-dose radiation to precisely defined target volumes and is an effective locally ablative treatment option for both primary tumours and oligometastases in various settings, including lesions in the abdomen or pelvis. However, SBRT in these regions faces considerable challenges such as inter-fractional organ motion and anatomical deformation, which can compromise treatment precision.\n\nMR-guided SBRT offers a solution, providing superior soft-tissue contrast and enabling real-time, online treatment plan adaptation over the course of SBRT. This approach reduces the risk of geographical miss and overdose to adjacent, vulnerable OARs. Currently, MR-guided SBRT uses a fixed dose per fraction, only adjusting target volume and OAR contours for anatomical changes when performing plan adaptation. However, overlaps between planning target volumes (PTVs) and dose-limiting OARs regularly require compromises in PTV coverage. To address this, AF aims to also adjust dose per fraction based on daily PTV-OAR overlap. With this approach, more dose is applied on treatment days with less PTV-OAR overlap while less dose is applied on days with more PTV-OAR overlap. This trial assesses the feasibility of AF in MR-guided SBRT for abdominal and pelvic tumours that show PTV-overlap with one or more dose-limiting OARs, ultimately aiming to enhance PTV dose coverage without increasing toxicity.",[268,269],"Abdominal Tumor","Pelvic Tumor",[271,272,214,273],"adaptive radiotherapy","stereotactic body radiotherapy","MR-guided radiotherapy","2026-06-29",{"date":172,"type":33},{"date":277,"type":33},"2026-06-16",{"date":279,"type":22},"2028-12",{"name":39,"class":40},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":69},"100614825","phase-2-vortioxetine-for-newly-diagnosed-glioblastoma-100614825","NCT07284628","Vortioxetine for Newly Diagnosed Glioblastoma","A Phase II Drug Repurposing Trial of Vortioxetine for the Treatment of Patients With Newly Diagnosed Glioblastoma","ReVoGlio","Inclusion Criteria:\n\n1. Male or female, age ≥18 years\n2. Patients with histologically confirmed newly diagnosed glioblastoma per CNS WHO 2021 classification\n3. O6-methylguanine DNA methyltransferase (MGMT) promotor methylation status known or tissue available for testing\n4. Karnofsky performance status (KPS) ≥ 70%\n5. Intent to treat with standard radiochemotherapy per EANO guidelines (radiotherapy will 60 Gy in 1.8-2 Gy fractions. Concomitant chemotherapy with temozolomide (75 mg\u002Fm2 daily throughout radiotherapy, including at weekends) followed by six cycles of maintenance temozolomide (150-200 mg\u002Fm2, 5 out of 28 days). Short course radiotherapy at 40 Gy is not allowed.\n6. Female patients must be either documented not to be Women of Childbearing Potential (WOCBP) or must have a negative pregnancy test within 14 days of starting treatment. Additionally WOCBP must agree to use, from the screening to 6 months following the last study drug administration, highly effective contraception methods, as defined by the \"Recommendations for contraception and pregnancy testing in clinical trials\" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu\u002Fctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner. WOCBP are defined as females who have experienced menarche, are not postmenopausal (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).\n7. Male subjects able to father children must agree to use two acceptable methods of contraception throughout the study and during 6 months following the last study drug administration (e.g., condom with spermicidal gel). Double-barrier contraception is required.\n8. Personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.\n9. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.\n\nExclusion Criteria:\n\n1\\. Prior treatment for newly diagnosed glioblastoma except surgery. 2. Intent to be treated with tumor-treating fields. 3. Inability to undergo contrast-enhanced MRI. 4. Inadequate bone marrow, renal and hepatic function:\n\n* Absolute neutrophil count (ANC) \\\u003C 1.5 x 10.9\u002FL; platelets \\\u003C 100 x 10.9\u002FL\n* Hemoglobin (Hb) \\\u003C 9.0 g\u002Fdl. Blood marrow values must be measured independently of transfusion.\n* Chronically impaired renal function as indicated by creatinine clearance \\\u003C 50 mL\u002Fmin or serum creatinine \\> 1.5 upper limit of normal (ULN).\n* Inadequate liver function (ALT, AST, ALP ≥ 2.5 x ULN) 9. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.\n\n  10\\. Any contra-indication to vortioxetine. 11. Medically documented history of active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g., risk of doing harm to self or others), or patients with active severe personality disorders.\n\n  12\\. Pregnancy or breast feeding. 13. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.\n\n  14\\. Concurrent malignancies unless the patient has been disease-free without intervention for at least one year.\n\n  15\\. Requirement of concurrent use of other anti-cancer treatments or agents other than study medication.",{"count":290,"type":22},78,[81],"There is a very urgent need to improve on the currently limited treatment options for patients with glioblastoma. Despite extensive knowledge on the molecular pathogenesis of glioblastoma obtained through genomic, transcriptional and proteomic profiling, targeted therapy efforts have not yielded major advances, likely because of interindividual and intraindividual tumor heterogeneity and redundant oncogenic pathway activation.\n\nAccordingly, there is a strong rationale to approach the challenge of glioblastoma from a different angle, e.g., by ex vivo drug sensitivity profiling which is agnostic to the molecular profile of a tumor. This approach that we have termed \"pharmacoscopy\", has previously been explored in liquid cancers and probably led to improved patient outcomes. Using pharmacoscopy, the antidepressant drug, vortioxetine, has been identified as a lead candidate for further exploration in patients with glioblastoma. Vortioxetine also demonstrated synergistic anti-glioma activity in combination with temozolomide or lomustine.\n\nThe ReVoGlio trial aims at demonstrating that vortioxetine, a drug selected based on ex vivo drug profiling (pharmacoscopy), is of benefit for patients with newly diagnosed glioblastoma.",[294],"Glioblastoma",[294,296,297],"Drug repurposing","Vortioxetine","2026-06-25",{"date":274,"type":33},{"date":301,"type":33},"2026-06-24",{"date":303,"type":22},"2029-06",{"name":39,"class":40},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":23,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":118},"100563762","phase-2-ex-vivo-drug-response-evaluation-for-next-generation-care-of-brain-metastases-100563762","NCT06620380","Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases","EViDENCE-BM","Inclusion Criteria:\n\n* Patients must be 18 years or older on the day of signing the informed consent, female or male.\n* Patients must have a Karnofsky performance status of 60 or more\n* Patients must have limited systemic therapeutic options as per treating physician judgement. The number of previous lines of therapies is not limited.\n* Patients with a tumor with a targetable oncogenic driver mutation should have already been treated with a targeted agent and options must have been exhausted.\n* Patients must have a clinical indication for surgery for probable brain metastasis\n* Patients will be considered eligible for the study only if the diagnosis of brain metastasis has been histologically confirmed on the sample obtained during the surgery performed after signing the informed consent form for the trial.\n* Any type of primary cancer is allowed: breast cancer, lung cancer, melanoma, other cancers. Patients may have several primary cancers.\n* Patients must have adequate bone marrow, renal and hepatic function documented at screening before surgery\n* Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test\n* Patients must have the ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.\n* Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.\n\nExclusion Criteria:\n\n* Patients with rapidly progressive systemic disease\n* Patients with inability to undergo brain MRI evaluation.\n* Patients with progressive parenchymal brain metastases with an indication for requiring whole brain radiotherapy after surgery. Focal brain radiotherapy after surgery is allowed.\n* Judgement by the investigator that the patient is unlikely to comply with study procedures, restrictions and requirements.\n* Intention to become pregnant during the course of the study.\n* Female who are pregnant.\n* Female who are breastfeeding and who do not agree to discontinue nursing prior to the first treatment initiated during the study.\n* Sexually active males and females of childbearing potential who are not willing to use an effective contraceptive method during the study. Male participants who do not agree not to donate sperm.",{"count":313,"type":22},102,[81],"Pharmacoscopy refers to an ex vivo real-time drug sensitivity profiling platform that has been shown to be of value in the treatment of leukemia (Snijder et al. 2017) (Kornauth et al. 2022) and may help to identify novel treatment opportunities for brain tumors as well (Lee et al. 2022). The rationale for pharmacoscopy-based drug sensitivity testing on real-time patient biopsies or surgery material is multiple: measuring drug response and sensitivity directly in real-time patient material, overcomes the problem of limited molecular biomarkers for established targeted therapeutic options and can identify effective drugs even for non-targeted therapies such as chemotherapy. It can also identify hitherto unknown specific vulnerabilities of cancer cells. Furthermore, testing directly on patient material overcomes the limitations of patient-derived cell cultures, organoids, and patient xenografts, as their prolonged culture times risk cellular adaptations and clonal selection that alter drug sensitivity. Pharmacoscopy maintains the tumor cell composition, including bystander cells or tumor microenvironment, and limits cell culture to max 48 hours. Furthermore, pharmacoscopy measures drug responses on a single-cell and on a high-content level, uniquely allowing to measure the drug sensitivity of tumor cells, and allowing to compare it to the drug cytotoxicity on healthy cells from the same patient. This relative readout has previously been shown to be essential for the correct prediction of a clinical response in haematological malignancies (Snijder et al. 2017) (Kornauth et al. 2022).\n\nThe aim of this study is to generate preliminary data regarding superiority of the personalized pharmacoscopy-guided approach compared to a standard non-pharmacoscopy-guided approach, in patients with brain metastases with an indication for surgery, and limited therapeutic systemic options according to the treating physician.",[317,318],"Brain Metastases","Brain Metastases, Adult",{"date":274,"type":33},{"date":321,"type":33},"2025-09-12",{"date":323,"type":22},"2027-06",{"name":39,"class":40},{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":149,"sex":50,"minAge":19,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":69},"100644284","fasting-exercise-and-diet-to-activate-autophagy-in-depression-100644284","NCT07664540","Fasting, Exercise, and Diet to Activate Autophagy in Depression","Targeting Autophagy in Depression: Fasting, Exercise, Diet","AutoFast","Inclusion Criteria:\n\n* age: 18-40 years\n* BMI: between 18.5 and 24.9 kg\u002Fm2 (SG1\u002F2) or BMI between 25.0 and 39.9 kg\u002Fm2 (SG3\u002F4)\n* ability to understand the study procedure and give consent\n* Written informed consent\n* SG1 women: any fitness level\n* SG2 men: VO2max \\\u003C 45 ml\u002Fkg\u002FKG29,30\n* Available to conduct CPET on menstrual cycle days 1-5 (SG1\u002F3)\n* No infection with HIV or Hepatitis B\u002FC\n\nExclusion Criteria:\n\n* No infectious illness for at least two weeks prior to the test\n* No vitamin supplementation during the week prior to the performance test\n* SG3 and SG4: More than 1 hour moderate exercise per week\n* No use of hormonal contraceptives in the last 6 months before the onset of the study (SG1\u002F3)\n* a clinically diagnosed menstrual disorder (e.g., polycystic ovarian syndrome or amenorrhea) (SG1\u002F3)\n* having given birth within the 12 months before inclusion in the study (SG1\u002F3)\n* pregnancy or breastfeeding (SG1\u002F3)\n* premenstrual dysphoric disorder (PMDD) (SG1\u002F3)\n* history of epileptic seizure\n* history of depression\n* history of manic or psychotic episode\n* existing\u002Fcurrent eating disorders (bulimia nervosa, anorexia nervosa) within the past 5 years\n* inability to communicate adequately in speech\n* inability to follow instructions\n* regular use of medication other than thyroxine\n* alcohol consumption as equivalent doses of more than 12 g of pure alcohol per day on average for women and 24 g of pure alcohol per day for men\n* vegan diet\n* daily nicotine consumption\n* currently or history of (regular) consumption of illegal drugs within the last year\n* known diseases of the cardiovascular system\n* arterial hypertension above 160\u002F90 mmHg at rest\n* known pulmonary diseases\n* arthritis and rheumatic diseases and conditions\n* hematologic diseases\n* bronchial asthma\n* surgery less than 4-6 months ago\n* orthopedic or other diseases (e.g. neurological) that preclude maximum load on the bicycle ergometer\n* anemia (\\\u003C12.0 g\u002Fdl for women and \\\u003C14.0 g\u002Fdl for men)","40 Years",{"count":79,"type":22},[25],"Depression is a common mental health condition that affects millions of people worldwide and is a leading cause of disability. Although current treatments can be effective, many patients do not fully recover or experience long-term improvement. This study aims to better understand how lifestyle factors such as physical activity and diet-related processes may influence biological mechanisms that could be linked to depression.\n\nThe study focuses on a natural cellular process called autophagy, which helps cells remove damaged components and maintain healthy function. Autophagy is influenced by energy availability in the body and may be affected by behaviors such as physical exercise and caloric restriction. Early evidence suggests that changes in autophagy may also be linked to mood regulation and depression, but this relationship is not yet well understood in humans.\n\nIn this exploratory study, we will investigate how physical activity influences autophagy and related metabolic and molecular processes in healthy adults. We will also examine whether these effects differ between individuals with different body weight and fitness levels, and between women and men.\n\nA total of approximately 120 healthy adults aged 18 to 40 years will participate. Participants will be divided into four groups based on sex and body weight (normal weight or overweight). Each participant will attend study visits at the University Hospital Zurich and perform a standardized cycling exercise test under medical supervision.\n\nDuring the exercise test, participants will perform a graded cycling protocol that gradually increases in intensity until exhaustion. We will collect small blood samples from a vein and from a fingertip at several time points before, during, and after exercise. Saliva samples will also be collected to measure stress-related hormones. Additional measurements include heart rate, breathing parameters, oxygen consumption, and physical performance.\n\nBlood and saliva samples will be analyzed using advanced laboratory techniques to study changes in metabolism, immune signaling, hormones, gene activity, and markers related to autophagy. These analyses will help identify biological pathways that are activated by exercise and may be relevant to brain health and depression.\n\nParticipants will undergo medical screening before inclusion to ensure safety. Individuals with certain medical conditions or factors that could interfere with the study results will not be included. Participation is voluntary, and participants may withdraw at any time without consequences.\n\nThe study involves minimal risks associated with blood sampling and intense physical exercise, which will be performed under close medical supervision. The expected benefit is improved scientific understanding of how lifestyle-related biological processes may be linked to mental health, which could support the development of new preventive or therapeutic strategies for depression in the future.",[338,159],"Depression - Major Depressive Disorder",[340,164,341,167,342,343,166,344],"autophagy","depression","autophagy flux","performance testing","proteomics","2026-06-17",{"date":301,"type":33},{"date":348,"type":22},"2026-09-11",{"date":350,"type":22},"2029-09-30",{"name":39,"class":40},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":149,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":363,"conditions":364,"keywords":366,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":4},"100642879","phase-4-effect-of-supplemental-oxygen-therapy-on-neurocognitive-performance-in-healthy-highlanders-100642879","NCT07651917","Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders","SPIRIT_1","Inclusion Criteria:\n\n* Signed written consent\n* Age \\>18\n* Kyrgyz ethnicity\n* Born, raised and living at approximately 2500 m\n* Native or fluent in Russian language\n\nExclusion Criteria:\n\n* Severe disease such as unstable hypertension, coronary heart disease, pulmonary diseases, others.\n* Regular use of medication that interfere with sleep or breathing such as benzodiazepines, opioids, acetazolamide\n* Heavy smoking of \\>20 cigarettes per day\n* Not able to read or adhere to the study protocol",{"count":360,"type":22},50,[362],"PHASE4","Exposure to high altitudes, defined as locations above 2500 m, has been shown to cause cognitive alternations due to reduced blood oxygenation (SpO2). However, it remains to be determined whether cognitive changes are present in highlanders living at moderate altitudes (2500 m) and whether cognitive alterations are reversible with supplemental oxygen therapy (SOT).",[365],"Neurocognition",[367,368,369],"Hypoxia","Altitude","Supplemental oxygen therapy","2026-06-10",{"date":277,"type":33},{"date":373,"type":22},"2026-06-18",{"date":375,"type":22},"2026-07-31",{"name":39,"class":40},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":23,"phases":386,"briefSummary":387,"conditions":388,"keywords":394,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":69},"100639454","early-detection-of-amyloidosis-in-monoclonal-gammopathy-using-nuclear-medicine-imaging-100639454","NCT07624760","Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging","Early Detection of Light-Chain Amyloidosis in Monoclonal Gammopathy Using 18F-Florbetaben PET\u002FMR: a Prospective, Single-Center, Observational Study","MGUS-PET","Inclusion Criteria:\n\n* Participation in the COSMO-AL study\n* Available biopsy test result\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnant or lactating women",{"count":360,"type":22},[25],"The goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET\u002FMR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy. The main question it aims to answer is: Can ¹⁸F-florbetaben PET\u002FMR identify systemic amyloid deposits across clinically and histologically defined patient groups?\n\nParticipants will:\n\n* Be screened for eligibility and asked to sign an informed consent form\n* Have their vital signs measured\n* Receive a single intravenous injection of approximately 300 MBq ¹⁸F-florbetaben (Neuraceq®), followed by whole-body PET\u002FMR imaging from skull base to below the kidneys. If MRI is contraindicated (e.g., pacemaker, severe claustrophobia), PET\u002FCT will be performed instead. The scan takes approximately one hour, during which participants lie still in the scanner\n* Be monitored during and after the scan for any side effects or adverse events\n* Complete study participation at the end of the imaging session (single visit, no follow-up required)",[389,390,391,392,393],"Monoclonal Gammopathy","Monoclonal Gammopathy of Undetermined Significance (MGUS)","Multiple Myeloma","AL Amyloidosis","Systemic Amyloidosis",[395,396,397,398,399,400,401,402,403],"MGUS","MGCS","Amyloid PET","PET\u002FMRI","Florbetaben","Early detection","Systemic amyloidosis","Monoclonal gammopathy","AL amyloidosis","2026-05-28",{"date":406,"type":33},"2026-06-03",{"date":408,"type":22},"2026-10",{"date":410,"type":22},"2028-05",{"name":39,"class":40},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":149,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":69},"100474517","analysis-of-exhaled-breath-from-patients-with-lung-airway-diseases-bigexbress-100474517","NCT05458934","Analysis of Exhaled Breath From Patients With Lung-\u002FAirway Diseases (BigExBrESs)","BigExBrESs","Inclusion Criteria:\n\n* Signed informed consent\n* Age ≥ 18 years at study entry\n\nExclusion Criteria:\n\n* Physical or intellectual impairment precluding informed consent or protocol adherence\n* Known pregnancy",{"count":420,"type":22},5000,"Ananlyis of exhaled breath of patients with lung-\u002Fairway diseases to identify and distinguish respiratory diseases, and improve the disease manangament.",[423],"Lung-\u002FAirway Diseases",{"date":137,"type":33},{"date":426,"type":33},"2021-05-11",{"date":428,"type":22},"2030-12-31",{"name":39,"class":40},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":149,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":69},"100474292","exhaled-breath-analysis-in-human-subjects-100474292","NCT05456009","Exhaled Breath Analysis in Human Subjects","Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Human Subjects","Inclusion Criteria:\n\n* \\>= 18 years\n* Informed consent\n\nExclusion Criteria:\n\n* specific exclusion criteria for different subgroups",{"count":438,"type":22},1500,"Identification of exhaled breath pattern of human subjects",[441],"Exhaled Breath Pattern After Medication Intake, in OSA Patients, or Other Pulmonary Diseases",{"date":137,"type":33},{"date":444,"type":33},"2019-02-19",{"date":446,"type":22},"2030-03-01",{"name":39,"class":40},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":459,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":69},"100289902","deep-brain-stimulation-in-patients-with-incomplete-spinal-cord-injury-for-improvement-of-gait-100289902","NCT03053791","Deep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait","A Phase I\u002FII Open-label Multicenter Trial to Evaluate Safety and Preliminary Efficacy of Unilateral Deep Brain Stimulation of the Mesencephalic Locomotor Region in Patients With Incomplete Spinal Cord Injury","DBS-SCI","Inclusion Criteria:\n\n1. Informed Consent\n2. Participation in two assessment sessions before enrollment (Screening and baseline)\n3. Willingness and ability to comply with the protocol and to attend required study training and visits\n4. Male or female subjects\n5. Age 18-75\n6. Motor incomplete SCI\n7. Level of lesion: T10 and above, based on AIS level, preservation of sacral function\n8. Focal spinal cord disorder caused by either trauma or non-traumatic and non-progressive condition (like hemorrhage, benign tumor)\n9. Minimum 3 months of recovery after SCI\n10. Completed in-patient rehabilitation program\n11. WISCI II, level \\>2 (0-20 items): assistance of one or more persons. Ability to walk at least 10 meters\n12. Stable medical and physical condition.\n13. Adequate care-giver support and access to appropriate medical care in patient's home community\n\nExclusion Criteria:\n\n1. Enrollment of the investigator, his\u002Fher family members, employees and other dependent persons\n2. Limitation of standing and walking function based on accompanying (CNS) disorders\n3. Cardiovascular disorders restricting physical training or peripheral nerve disorders\n4. Implanted technical devices (pacemaker, defibrillator)\n5. History of significant autonomic dysreflexia\n6. Cognitive disorders\u002Fbrain damage\n7. Drug refractory epilepsy\n8. Severe joint contractures disabling or restricting lower limb movements\n9. Haematological disorders with increased risk of bleeding during surgical interventions\n10. Participation in another study with investigational drug within the 30 days preceding and during the present study\n11. Congenital or acquired lower limb abnormalities (affection of joints and bone)\n12. Women who are pregnant or breast feeding or planning a pregnancy during the course of the study\n13. Lack of safe contraception\n14. Inability of the participant to follow the procedures of the study, e.g. due to language problems, psychological problems, dementia etc.\n15. Known or suspected non-compliance, drug or alcohol abuse\n16. Current or prior malignancy","75 Years",{"count":458,"type":22},5,[25],"Spinal cord injuries are anatomically mostly incomplete, showing tissue bridges of the spinal cord at the injury site. Of the 60% functionally incomplete patients, about half face a life in the wheelchair. Besides conventional rehabilitation, no prominsing further treatment options exist. One of the most plastic systems involved in locomotion is the pontomedullary reticulospinal tract, which is the oldest locomotor command system existing in most vertebrates, including primates. Muscle activation patterns for limb movements are programmed in the spinal cord and have to be activated and coordinated through commands from the so called mesencephalic locomotor region (MLR). The MLR consists of nerve cells in the lower mesencephalic tegmentum sending uni- and bilateral signals through the medullary reticulospinal tracts. Classical physiological studies showed that electrical stimulation of the MLR induce locomotion. For the first time this approach was transferred and recently published in a model of induced incomplete spinal cord injury by the Schwab group. Rats severly impaired in motor hindlimb control with only 10-20% spared white matter, recovered with fully functional weight bearing locomotion under MLR deep brain stimulation (DBS). Even rats with only 2-10% spared white matter regained weight supporting stepping. DBS is a clinical standard treatment option in patients with movement disorders but does not relieve all symptoms. Therefore, small studies of MLR stimulations have been safely used in Parkinsonian patients showing freezing of gait and frequent falls with variable results. In a translational approach, we aim at performing a multidisciplinary phase one clinical trial with 5 patients and incomplete spinal cord injury. With the means of our established universitary setup for DBS treatments the operations will be performed unilaterally under local anaesthesia in the Division of Neurosurgery, USZ, with perioperative electrophysiological recordings, clinical assessments and gait analysis under test stimulation in the Spinal Cord Injury Center Balgrist.",[462],"Spinal Cord Injury",[464,465,466,467,468,469,470,471,472],"Deep brain stimulation","DBS","Spinal cord injury","SCI","Paraplegia","Mesencephalic locomotor region","MLR","Pedunculopontine nucleus","PPN",{"date":137,"type":33},{"date":475,"type":33},"2018-03-15",{"date":477,"type":22},"2027-12",{"name":39,"class":40},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":149,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":41},"100557502","direct-measurement-of-ingestive-behaviour-in-relation-to-sex-differences-and-gastrointestinal-hormone-levels-in-patients-after-metabolic-and-bariatric-surgery-100557502","NCT06538948","Direct Measurement of Ingestive Behaviour in Relation to Sex Differences and Gastrointestinal Hormone Levels in Patients After Metabolic and Bariatric Surgery","DIBASH","Inclusion Criteria:\n\n* Age ≥ 18 year\n* BMI ≥ 35 kg\u002Fm2 for patients with planned RYGB or SG operation\n* BMI ≥ 30 kg\u002Fm2 for external controls affected by obesity but no planned RYGB or SG within the next 12 months, and\n* BMI ≥ 18.5 kg\u002Fm2 and ≤ 24.9 kg\u002Fm2 for controls without obesity.\n\nExclusion Criteria:\n\n* history of previous bariatric operations and\u002F or revisional surgery (e.g., alteration of limb lengths after primary RYGB),\n* smoking,\n* established diagnosis of type 1 or 2 diabetes mellitus, and\n* polycystic ovary syndrome (PCOS).",{"count":487,"type":22},420,"Bariatric surgery (BS), especially procedures like Sleeve Gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), is the most effective treatment for obesity. Yet, the exact mechanisms governing its effect are somewhat elusive, with current research mainly focusing on post-operative food intake outcomes based on self-reported data, which might not fully capture the nuanced changes in eating behaviours.\n\nTo address these gaps, our study plans to employ the newly developed \"drinkometer\", a device capable of analysing the intricate changes in drinking behaviour following BS. This tool promises to bring a more detailed perspective to the changes in ingestive behaviours, bypassing the inaccuracies of self-reporting methods. By expanding our research to encompass diverse patient demographics and examining potential links to physiological shifts like gut hormone level alterations, the study aims to provide a more rounded understanding of the long-term impacts of BS on eating behaviours.",[490],"Obesity",[490,492,493,494,495],"Ingestive Behaviour","Bariatric Surgery","Gut Hormones","Drinkometer","2026-05-14",{"date":498,"type":33},"2026-05-18",{"date":500,"type":33},"2024-02-13",{"date":502,"type":22},"2027-12-31",{"name":39,"class":40},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":149,"sex":50,"minAge":19,"maxAge":510,"enrollmentInfo":511,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":69},"100550146","pain-phenotyping-in-patients-with-neuropathic-pain-after-spinal-cord-injury-100550146","NCT06443281","Pain Phenotyping in Patients With Neuropathic Pain After Spinal Cord Injury","Inclusion Criteria:\n\n* Spinal injury cohort - general inclusion criteria:\n* Aged between 18-80 years\n* Traumatic and non-traumatic etiology\n* Para- and tetraplegic SCI\n* Complete and incomplete SCI\n* SCI with and without neuropathic pain\n* Additional inclusion criteria for longitudinal study:\n* SCI since less than one month\n* Additional inclusion criteria for cross-sectional study:\n* SCI since more than one year\n* Control cohorts with peripheral neuropathy:\n* General inclusion criteria:\n* Aged between 18-80 years\n* Neurological disorder affecting the peripheral nervous system (i.e., peripheral neuropathy)\n* Peripheral neuropathy with or without neuropathic pain\n* Additional inclusion criteria for longitudinal study:\n* Peripheral neuropathy since less than one month\n* Additional inclusion criteria for cross-sectional study:\n* Peripheral neuropathy since more than one year\n* Control cohorts without neuropathy \u002F healthy volunteers\n* General inclusion criteria:\n* Aged between 18-80 years\n* No medical condition affecting the peripheral and\u002For central nervous system (e.g., pain, systemic disease, psychological disorder)\n\nExclusion Criteria:\n\n* Inability to follow study instructions\n* Pregnancy\n* Medically manifested psychological disorder\n* Medical condition affecting the peripheral and\u002For central nervous system other than the desired experimental condition (e.g., additional peripheral neuropathy in the SCI cohort)","80 Years",{"count":512,"type":22},300,"The development of neuropathic pain is one of the most debilitating sequels after a spinal cord injury (SCI). The overall aim of this study is to investigate potential underlying pathophysiological mechanisms of neuropathic pain after SCI. The functionality of the nociceptive pathway in humans as well as its plastic changes following SCI will be inferred with sophisticated sensory and pain phenotyping using quantitative sensory testing (i.e., psychophysical measures), objective neurophysiological measures of pain processing and the recording of pain-related autonomic responses (i.e., galvanic skin response, cardiovascular measures and pupil dilation). In addition, the interplay between the somatosensory and autonomic nervous system and its association with the development and maintenance of neuropathic pain after SCI will be investigated.",[515,516,517,518],"Spinal Cord Injuries","Pain, Neuropathic","Nociceptive Pain","Neuropathy","2026-05-12",{"date":521,"type":33},"2026-05-15",{"date":523,"type":33},"2024-04-17",{"date":525,"type":22},"2030-04-30",{"name":39,"class":40},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":150,"minAge":19,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":542,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":69},"100638328","natural-cervical-ripening-to-prevent-pharmacological-induction-of-labor---a-pilot-study-100638328","NCT07587632","Natural Cervical Ripening to Prevent Pharmacological Induction of Labor - a Pilot Study.","Cervinat","Inclusion Criteria:\n\n* Singleton gestation\n* Non-insulin dependent, dietetically managed gestational diabetes\n* Greater than or equal to 34 weeks.\n* Planned vaginal birth at the University Hospital of Zurich\n* Planned IOL for 40 weeks of gestation.\n* Communication in German and\u002For English language possible.\n\nExclusion Criteria:\n\n* Pregnant women with multiple gestation\n* Fetal macrosomia \\>95th percentile\n* Intrauterine growth restriction \\\u003C3rd percentile\n* Already in labor (regular contractions or premature rupture of membranes (PROM)\n* Patients scheduled for IOL before 40 weeks\n* Insulin-dependent diabetes\n* Planned cesarean section\n* Planned birth in an external hospital\n* Inability to follow the procedures e.g. due to language problems, psychological disorders",{"count":535,"type":22},74,[25],"As of today, around 25% of all vaginal births happen after induction of labor (IOL). The internal guidelines of the University Hospital Zurich currently recommend pregnant women with a non-insulin dependent gestational diabetes an IOL around term. One possibility to prevent an IOL and increase the chance for a spontaneous onset of birth is a ripening of the cervix by alternative methods in an outpatient setting. The primary objective of this study is to evaluate the effect of natural cervical ripening methods on the time interval between 37 weeks (beginning of the intervention) and the onset of spontaneous labor.",[539,540,541],"Pregnancy","Induction of Labor","Gestational Diabetes Mellitus (GDM)",[543,544,545,546,547,548],"gestational Diabetes","Induction of labor","cervical ripening","pregnancy","colostrum banking","membrane sweeping","2026-05-07",{"date":496,"type":33},{"date":552,"type":33},"2026-04-10",{"date":554,"type":22},"2029-12-31",{"name":39,"class":40},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":563,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":566,"briefSummary":567,"conditions":568,"keywords":572,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":69},"100414125","emdr-treatment-in-ptsd-following-cardiac-events-100414125","NCT04672551","EMDR Treatment in PTSD Following Cardiac Events","EMDR_PTSD_MI","Inclusion Criteria:\n\n* Age between 18-70 years\n* Men or women\n* STEMI (irrespective of troponin, but ST-elevation) or non-STEMI (troponin positive) at the time of the cardiac event, as verified by the cardiologist\n* Diagnosis of PTSD caused by the cardiac event\n\nExclusion Criteria:\n\n* Psychotic disorder, bipolar disorder, substance abuse as measured with the Mini International Neuropsychiatric Interview (M.I.N.I)\n* Acute suicidal ideation as assessed with the M.I.N.I.\n* Non-selective beta blockers (e.g., propranolol) during the study period\n* Ongoing psychological\u002Fpsychiatric treatment outside of the trial during the study period\n* Visionary problems, e.g. strabismus, which does not allow adequate eye movements\n* Insufficient knowledge of the German language\n* Expected inability or willingness to follow the study protocol\n* Regular medication with benzodiazepine","70 Years",{"count":565,"type":22},60,[25],"Cardiac events can often result in debilitating and persistent psychological symptoms. A key question involves whether optimal treatment of cardiac-induced posttraumatic stress disorder (PTSD) reduces PTSD symptoms and thereby may offset the risk of recurrent or worsening cardiovascular disease. Cardiac-induced PTSD 1) is prevalent, 2) features symptoms unique to internal ongoing somatic threat, with fears and worries that can be distinguished from PTSD resulting from external causes, 3) is persistent, 4) is associated with negative physical and emotional consequences, and 5) has not been the subject of randomized-controlled treatment trials (RCT). There is preliminary evidence suggesting that patients with cardiac-disease induced PTSD might particularly profit from EMDR. Nevertheless, this possibility has not been tested in cardiac-induced PTSD. Currently, patients with cardiac-induced PTSD are not routinely offered trauma-focused therapies, with a lack of scientific evidence likely being one major reason for this omission. If our proposed RCT shows that EMDR can be an effective treatment for patients with ACS-induced PTSD, EMDR could be routinely implemented as first-line treatment. The RCT outcomes might inform larger trials to test whether poor prognosis in terms of major adverse cardiovascular events can be improved through EMDR in patients with cardiac-induced PTSD.",[569,570,571],"Posttraumatic Stress Disorder","Myocardial Infarction","Eye Movement Desensitization and Reprocessing",[573,574,575,576],"PTSD","MI","ACS","EMDR","2026-05-06",{"date":549,"type":33},{"date":580,"type":33},"2020-11-21",{"date":582,"type":22},"2027-11-30",{"name":39,"class":40},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":149,"sex":50,"minAge":4,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":592,"conditions":593,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":69},"100318198","pathophysiology-of-inborn-immunodeficiencies-100318198","NCT03422614","Pathophysiology of Inborn Immunodeficiencies","Pathophysiologie Angeborener Immundefekte","Inclusion Criteria:\n\n* Clinical diagnosis of an inborn error of immunity (primary immunodeficiency, PID)\n* Clinically healthy (non-age matched) volunteer\n\nExclusion Criteria:\n\n* exclusion of an inborn error of immunity\n* secondary immunodeficiency\n* refusal to enter the study",{"count":512,"type":22},"The pathophysiology of primary immunodeficiencies (PID), which encompass a broad range of different diseases with susceptibility to infection and\u002For a deregulated inflammatory response, is poorly understood. Available treatments are often not specific for a distinct target and might be associated with side effects. To elucidate pathophysiology of different PIDs, stool, urine, blood, tissue biopsies and\u002For bone marrow will be collected and analysed for anti-microbial activity and inflammatory response. In a second step, targeted treatment for different PIDs might be developed preclinically and ex vivo according to underlying pathophysiology.",[594],"Primary Immune Deficiency Disorder","2026-05-05",{"date":577,"type":33},{"date":598,"type":33},"2015-03-01",{"date":600,"type":22},"2033-03-30",{"name":39,"class":40},{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":50,"minAge":609,"maxAge":610,"enrollmentInfo":611,"targetDuration":4,"studyType":23,"phases":613,"briefSummary":614,"conditions":615,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":622,"locationsCount":118},"100292176","phase-2-oral-propranolol-for-prevention-of-threshold-retinopathy-of-prematurity-100292176","NCT03083431","Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity","RoProp","Inclusion criteria:\n\n* Preterm infant born before 28 week's gestation\n* Birth weight below 1250 g\n* At least 5 weeks of age (at randomisation)\n* PMA 310\u002F7 - 36 6\u002F7 weeks\n* Ophthalmoscopic evidence of incipient ROP (stage 1 or 2, with or without plus disease in any zone)\n* Written informed consent by parents or legal guardian, according to national requirements\n\nExclusion Criteria:\n\n* ROP stage ≥ 3, AP-ROP or suspected AP-ROP, or any other ROP requiring an intervention (study endpoint already reached).\n* Conditions that indicate open label propranolol such as: thyrotoxicosis, arterial hypertension or certain heart diseases (such as tetralogy of Fallot, paroxysmal supraventricular tachycardia, or long QT syndrome) etc.\n* Major congenital malformations or known chromosomal anomalies\n* Colobomas and other eye malformations\n* PHACE syndrome (posterior fossa anomalies, large infantile hemangiomas of the face, neck, and\u002For scalp, arterial lesions, cardiac abnormalities\u002Fcoarctation of the aorta, eye anomalies) (risk of cerebrovascular complications)\n* Very large hemangioma (risk of hyperkalemia), as judged by the attending physician\n* Medication of the infant with rifampicin or phenobarbitone (enhanced metabolic clearance)\n* Chronic kidney impairment (serum creatinine \\> 1.3 mg\u002Fdl \\[115 μmol\u002FL\\])\n* Severe liver dysfunction (ALT (GPT) \\> 900 U\u002FL)\n* Known hypersensitivity to propranolol or any of the excipients (see 6.3.1.)\n* Prinzmetal's angina, Raynaud's phenomenon (severe peripheral arterial circulatory disturbance), or pheochromocytoma (contraindications for propranolol in adults, not occurring in newborn infants)\n* Any circumstances that make the investigator believe that participation in the study leads to exceptional medical or organizational problems for the patient\n* Conditions that prohibit propranolol therapy such as: Atrio-ventricular block grade 2 or 3 hypertrophic cardiomyopathy, sinoatrial block, uncontrolled heart failure or cardiogenic shock, bronchial asthma\n* Medication of the infant or the mother if breastfeeding with clonidine, reserpine, angiotensin-converting enzyme inhibitors, angiotensin-receptor antagonists (contraindicated in preterm infants) or antiarrhythmic drugs including amiodarone, propafenone, lidocaine, digoxin\u002Fdigitoxin, quinidine, verapamil, diltiazem, bepridil (pharmacodynamic interaction)","5 Weeks","15 Weeks",{"count":612,"type":22},276,[81],"Extremely premature infants are at risk of developing a potentially blinding eye disease, called retinopathy of prematurity (ROP). Currently available treatment, consisting of laser surgery or injection of drugs into the eye balls, may prevent most but not all cases of permanent ROP-mediated blindness. Both types of treatment are associated with significant costs and side effects.\n\nAn orally administered drug commonly used to treat hypertension, propranolol, may be effective in halting progression of ROP to severe stages, as suggested by preliminary data from small studies. As severe (threshold) ROP is an overall rare disease, the effectiveness of propranolol in combating ROP can only be assessed in a large, multicenter randomized controlled trial involving hospitals caring for extremely preterm infants of diverse origin.",[616],"Retinopathy of Prematurity","2026-05-04",{"date":549,"type":33},{"date":620,"type":33},"2022-09-22",{"date":554,"type":22},{"name":39,"class":40},{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":629,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":50,"minAge":4,"maxAge":4,"enrollmentInfo":631,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":633,"conditions":634,"keywords":636,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":646,"locationsCount":69},"100557171","stop-stroke-stroke-outcome-prediction-in-the-acute-treatment-setting-100557171","NCT06534645","STOP-stroke: STroke Outcome Prediction in the Acute Treatment Setting","STOP-stroke: STroke Outcome Prediction in the Acute Treatment Setting - a Prospective, Single-center, Observational Study","STOP-STroke","Inclusion Criteria:\n\n* Patients from up to 18 years years of age without any upper age limit.\n* Patients with clinical suspicion of acute ischemic stroke (acute onset focal neurological deficit) at the discretion of the paramedic or treating physician within 24 hours of symptom onset including wake-up situation and unclear symptom onset planned for clinically indicated neuroimaging.\n* Patients with externally performed neuroimaging before admission or referral to the USZ will be included from the time point N2 on if no refusal of use of data is documented.\n\nExclusion Criteria:\n\n• Patients with documented objection of subsequent use of personal health data or patients who reject the use of personal health data during follow-up after initial informed consent by an independent physician in the acute setting. We will not include patients in the study if there is no written informed consent either from the patient her-\u002Fhimself, the next of kin or the independent physician.",{"count":632,"type":22},250,"The STOP-stroke project aims at improving prediction of outcome early after stroke. In order to achieve this, we need to understand reasons (important variables) for prediction in a real clinical prognostication process.\n\nWe aim to:\n\n1. Test the predictive performance of stroke neurologists for outcome prediction (NIHSS at 24 hours and 3 months and mRS at 3 months after stroke onset) prospectively and in a real clinical setting, and to explore the most important baseline variables in their prognostication process.\n2. Test the prediction performance of our DL models when being provided with structured clinical and\u002For imaging information from the same patients as the neurologists; and to discover most relevant features of the input data.\n3. Use the information gained from our experiments for improving our DL algorithm. This will include an error analysis on the missclassifications of models and neurologists to understand the pitfalls of both approaches. We anticipate to develop a robust, reliable and clinically feasible application ready for testing in a prospective, observational trial.",[635],"Stroke Outcome Prediction Supported by Deep Learning Algorithm",[637,638,639],"stroke outcome prediction","deep learning","AI in stroke","2026-05-03",{"date":549,"type":33},{"date":643,"type":33},"2024-10-29",{"date":645,"type":22},"2027-07-30",{"name":39,"class":40},""]